Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2023-11-17 00:00:00 ET · period of report 2023-11-15 · accession 0001209191-23-055717 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-17 | 2023-11-15 | BBIO | Valantine Hannah | Dir | M - OptEx | $8.45 | +2,915 | 4,679 | +165% | +$24.6K |
| D | 2023-11-17 | 2023-11-15 | BBIO | Valantine Hannah | Dir | S - Sale+OE | $30.00 | -2,915 | 1,764 | -62% | -$87.5K |
| D | 2023-11-17 | 2023-11-15 | BBIO | Valantine Hannah | Dir | M - OptEx | $0.00 | -2,915 | 102.0K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-15 | M | A | 2,915 | $8.45 | 4,679 | D | — | — | |
| 2 | Common | Common Stock | 2023-11-15 | S | D | 2,915 | $30.00 | 1,764 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2023-11-15 | M | D | 2,915 | $0.00 | 102,006 | D | $8.45 · — to 2032-06-22 | 2,915 Common Stock | (F2) 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. |